Search
Qiagen NV
QGENAdd to Watchlist
36.950USD
+0.370+1.01%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
8.00BMarket Cap
19.77P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Qiagen NV is 7.00, ranking 316 out of 389 in the Biotechnology & Medical Research industry. The average price target is 50.00, with a high of 57.00 and a low of 45.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
44.294
Target Price
+19.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Qiagen NV
QGEN
16
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Qiagen NV's expected revenue for the next quarter?
Qiagen NV's expected revenue is 528.83M.
What is Qiagen NV's price target?
Analysts forecast that Qiagen NV's price target is USD 50.00, with the highest forecast at USD 57.00 and the lowest forecast at USD 45.00.
How have Qiagen NVQGEN's recent earnings per share performed?
The market expectation was USD 0.33, while Qiagen NVQGEN's earnings per share (EPS) for the previous quarter was USD 0.50. EPS for the next quarter is expected at USD 0.60.
What is the analyst rating for Qiagen NV?
Based on the ratings of Qiagen NV's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
